The First AI Medical Device That Can Detect All Major Skin Cancers Just Received FDA Approval

With over 5 million cases flagged annually in the U.S., accurately diagnosing this disease is critical to patient survival. DermaSensor, an AI-powered medical marvel is primed to change the way skin cancer is diagnosed. On January 17, 2024, the US Food and Drug Administration (FDA) gave its nod to DermaSensor, making it the first of its kind to identify the top three skin cancers—melanoma, basal cell carcinoma, and squamous cell carcinoma.

DermaSensor, Inc., the company behind this innovation, harnesses elastic scattering spectroscopy (ESS) to scrutinize suspicious lesions at a cellular level. Priced at $199 monthly for five patients or $399 for unlimited use, it is set to shake up the medical landscape. With a proactive second opinion within seconds, DermaSensor manages to change the skin cancer detection space.